Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
11 January 2021 - 10:00PM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercialising
oral immunotherapeutics for the prevention and treatment of gut
pathogens, today is pleased to announce that Chief Executive
Officer, Dr Jerry Kanellos, will participate in the H.C. Wainwright
& Co. BioConnect 2021 Virtual Conference in January 2021 during
J.P. Morgan week.
Details of the events are as follows:
- H.C. Wainwright Virtual BioConnect Conference January 11 – 14,
2021: The company’s presentation will take place on Monday, January
11, 2021, at 6 a.m. US EST and will be available to all
conference-registered institutional investors. A copy of the
presentation will be available on Immuron’s website Monday, January
11, 2021.
- Webcasting link:
https://journey.ct.events/view/7c318482-d6ae-4782-8ae7-f7279b4d9cde
This release has been authorised by the
directors of Immuron Limited.
COMPANY CONTACT:
Dr Jerry Kanellos,
Ph.D.Chief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases. Immuron has a novel and safe
technology platform with one commercial asset generating revenue.
In Australia, Travelan® is a listed medicine on the Australian
Register of Therapeutic Goods (AUST L 106709) and is indicated to
reduce the risk of Travellers’ Diarrhea, reduce the risk of minor
gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licenced natural health product (NPN 80046016) and
is indicated to reduce the risk of Travellers’ Diarrhea. In the
U.S., Travelan® is sold as a dietary supplement for digestive tract
protection in accordance with section 403 (r)(6) of the Federal
Drug Administration (FDA).
About Travelan®Travelan® is an
orally administered passive immunotherapy that prophylactically
reduces the likelihood of contracting travelers’ diarrhea, a
digestive tract disorder that is commonly caused by pathogenic
bacteria and the toxins they produce. Travelan® is a highly
purified tabletized preparation of hyper immune bovine antibodies
and other factors, which when taken with meals bind to
diarrhea-causing bacteria and prevent colonization and the
pathology associated with travelers’ diarrhea. In Australia,
Travelan® is a listed medicine on the Australian Register for
Therapeutic Goods (AUST L 106709) and is indicated to reduce the
risk of Travelers’ Diarrhea, reduce the risk of minor
gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licensed natural health product (NPN 80046016) and
is indicated to reduce the risk of Travelers’ Diarrhea. In the
U.S., Travelan® is sold as a dietary supplement for digestive tract
protection.
About Travelers’
diarrheaTravelers’ diarrhea is a gastrointestinal
infection with symptoms that include loose, watery (and
occasionally bloody) stools, abdominal cramping, bloating, and
fever, Enteropathogenic bacteria are responsible for most cases,
with enterotoxigenic Escherichia coli (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a
significant proportion of cases. The more serious infections with
Salmonella spp. the bacillary dysentery organisms belonging to
Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with travelers’ diarrhea as they may be contracted
while travelling and initial symptoms are often
indistinguishable.
For more information visit:
http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Such statements include, but
are not limited to, any statements relating to our growth strategy
and product development programs and any other statements that are
not historical facts. Forward-looking statements are based on
management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock value. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to
the timing of starting and completing clinical trials;
uncertainties relating to preclinical and clinical testing; our
dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2024 to May 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From May 2023 to May 2024